Glenn Braunstein

Mar 11, 2015

Glenn Braunstein is Pathway Genomics' new chief medical officer, where he will oversee the company’s pharmacogenomics testing menu.

Previously, Braunstein was VP of clinical innovation and director of the thyroid cancer program at Cedars-Sinai Medical Center, where he also chaired the department of medicine. He was also the vice chair of the department of medicine at the David Geffen School of Medicine at the University of California, Los Angeles.

Breaking News

Genomadix Gets FDA 510(k) Clearance for Point-of-Care PCR System, CYP2C19 Test
Beethoven's Genome Offers Clues to Composer's Liver Disease, Family History
BostonGene, Little Warrior Foundation Partner to Develop Sarcoma-Specific Liquid Biopsy
Invitae, Deerfield Management Partner to Mine Test Data for Rare Disease Drug Development
Massive Bio, NeoGenomics Collaborate on AI-Driven Oncology Clinical Trial Matching

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.